Newest
-
Industry for Good: UNGLEP and Multinationals Jointly Building an ESG-Driven Global Career System for Youth in the AI Era
-
Used-car export wins wider approval with expanded scale
-
6 Best AI Design Tools Tested in 2026: What it's like to design with them
-
Axevor Announces Breakthrough in AI Quantitative Investment, Plans to Roll Out Quantitative Trading Services
I-Mab to Participate at the Piper Sandler Healthcare Conference
2024-11-22
I-Mab Biopharma
HaiPress

The 36th Annual Healthcare Conference will be held in New York,December 3-5,2024
ROCKVILLE,Md.,Nov. 21,2024 -- I-Mab (NASDAQ: IMAB,the "Company"),a U.S.-based global biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on December 4,2024.
Piper Sandler 36th Annual Healthcare Conference Presentation Details
Presentation Time
Wednesday,December 4 at4:30 p.m. ET
Presenters
Sean Fu,PhD,MBA,Chief Executive Officer
Phillip Dennis,MD,Chief Medical Officer
Webcast link
Here
Meetings
One-on-one and small group meetings:December 3 – 4,2024
Management
Participants
Sean Fu,Chief Executive Officer
Joseph Skelton,Chief Financial Officer
Phillip Dennis,Chief Medical Officer
Tyler Ehler,Senior Director,Investor Relations
The webcast will also be available under "Event Calendar" onI-Mab'sIR website
athttps://ir.i-mabbiopharma.com/
For more information,please contact your Piper Sandler representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based,global biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey. For more information,please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information,please contact:
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com
